Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Other Income (Minority Interest) represents par value or stated value of the subsidiary stock not owned by the parent company plus the minority interest's equity in the surplus of the subsidiary. Coloplast AS's Other Income (Minority Interest) for the
three
months ended in Jun. 2026 was $0 Mil. Its Other Income (Minority Interest) for the trailing twelve months (TTM) ended in Jun. 2026 was $0 Mil.
Coloplast AS (OTCPK:CLPBY) Other Income (Minority Interest) Explanation
Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company. It is reported on the consolidated income statement as a share of profit belonging to minority shareholders.
Coloplast AS Other Income (Minority Interest) Historical Data
* Premium members only.
The historical data trend for Coloplast AS's Other Income (Minority Interest) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coloplast AS Other Income (Minority Interest) Chart
Coloplast AS Other Income (Minority Interest) Calculation
Other Income (Minority Interest) represents par value or stated value of the subsidiary stock not owned by the parent company plus the minority interest's equity in the surplus of the subsidiary.
Other Income (Minority Interest) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Income (Minority Interest) of $0 Mil mean?
Coloplast AS (CLPBY) has a Other Income (Minority Interest) of $0 Mil as of Jun. 2026. Other Income (Minority Interest) represents par value of subsidiary stock plus the minority interest's equity in surplus of the subsidiary. View historical data on Coloplast AS and its competitors.
Is Coloplast AS's Other Income (Minority Interest) too high?
Coloplast AS's current Other Income (Minority Interest) is $0 Mil. Overall, Coloplast AS has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Other Income (Minority Interest) compare to ISRG and BDX?
Coloplast AS's Other Income (Minority Interest) of $0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Income (Minority Interest) for a Medical Devices & Instruments company?
A good Other Income (Minority Interest) depends on the Medical Devices & Instruments industry context. However, Other Income (Minority Interest) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Income (Minority Interest) mean?
A high Other Income (Minority Interest) can signal that a stock is expensive relative to its fundamentals. Other Income (Minority Interest) represents par value of subsidiary stock plus the minority interest's equity in surplus of the subsidiary. View historical data on Coloplast AS and its competitors. Coloplast AS's current Other Income (Minority Interest) is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.44, compared to a current price of $6.79 — trading 45.4% below its estimated fair value. The current Other Income (Minority Interest) is $0 Mil. Coloplast AS's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Income (Minority Interest) calculated?
Other Income (Minority Interest) is calculated from a company's financial statements. For Coloplast AS (CLPBY), the current Other Income (Minority Interest) is $0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBY) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $6.79 is trading 45.4% below its estimated GF Value™ of $12.44.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBY:
Other Income (Minority Interest): $0 Mil
GF Value™: $12.44 vs. price of $6.79 (45.4% below fair value)
No single metric tells the full story. See the CLPBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
72GF Score
Get the complete analysis for CLPBY
Other Income (Minority Interest) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBY has been successfully added to your 
